| pubmed-article:9256134 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9256134 | lifeskim:mentions | umls-concept:C0009402 | lld:lifeskim |
| pubmed-article:9256134 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:9256134 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:9256134 | lifeskim:mentions | umls-concept:C0214192 | lld:lifeskim |
| pubmed-article:9256134 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:9256134 | lifeskim:mentions | umls-concept:C0444889 | lld:lifeskim |
| pubmed-article:9256134 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:9256134 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:9256134 | pubmed:dateCreated | 1997-9-8 | lld:pubmed |
| pubmed-article:9256134 | pubmed:abstractText | The camptothecin derivative irinotecan has demonstrated clinical activity in metastatic colorectal carcinoma in both chemotherapy-naive and fluorouracil-refractory patients. 9-Aminocamptothecin (9-AC; NSC 603071), another camptothecin derivative, was selected for clinical development based on preclinical activity, including cures in human tumor xenografts resistant to standard anticancer agents. We report a phase II trial of 9-AC in patients with previously untreated metastatic colorectal carcinoma. | lld:pubmed |
| pubmed-article:9256134 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256134 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256134 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9256134 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256134 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9256134 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256134 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256134 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256134 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9256134 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:9256134 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:9256134 | pubmed:author | pubmed-author:GrahamSS | lld:pubmed |
| pubmed-article:9256134 | pubmed:author | pubmed-author:WingKK | lld:pubmed |
| pubmed-article:9256134 | pubmed:author | pubmed-author:ArbuckS GSG | lld:pubmed |
| pubmed-article:9256134 | pubmed:author | pubmed-author:PazdurRR | lld:pubmed |
| pubmed-article:9256134 | pubmed:author | pubmed-author:AbbruzzeseJ... | lld:pubmed |
| pubmed-article:9256134 | pubmed:author | pubmed-author:BradofJ EJE | lld:pubmed |
| pubmed-article:9256134 | pubmed:author | pubmed-author:BallardW PWP | lld:pubmed |
| pubmed-article:9256134 | pubmed:author | pubmed-author:Diaz-CantonEE | lld:pubmed |
| pubmed-article:9256134 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9256134 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:9256134 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9256134 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9256134 | pubmed:pagination | 2905-9 | lld:pubmed |
| pubmed-article:9256134 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:meshHeading | pubmed-meshheading:9256134-... | lld:pubmed |
| pubmed-article:9256134 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9256134 | pubmed:articleTitle | Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. | lld:pubmed |
| pubmed-article:9256134 | pubmed:affiliation | Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. rpazdur@notes.mdacc.tmc.edu | lld:pubmed |
| pubmed-article:9256134 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9256134 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9256134 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9256134 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9256134 | lld:pubmed |
